Gene clues could personalize ulcerative colitis treatment

NCT ID NCT07398586

Completed Knowledge-focused Sponsor: Second Affiliated Hospital of Wenzhou Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study examined whether differences in the IL-7 receptor gene are linked to the risk of developing ulcerative colitis and how well patients respond to the drug vedolizumab. Researchers enrolled 898 people, including those with UC and healthy controls, and analyzed their genetic profiles. The goal is to understand if genetic testing could one day help tailor treatment decisions for UC patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vedolizumab
What this could lead to: If successful, this could help doctors predict which ulcerative colitis patients will respond best to vedolizumab, leading to more personalized treatment.
What could go wrong: This is an observational genetic analysis, not a treatment trial. The findings may not change clinical practice and need further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colitis ulcer disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS (UC)

Contacts and locations

Locations

the Second Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.